Ćterna Zentaris (AEZS) Downgraded to Hold at Zacks Investment Research

Ćterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

A number of other equities analysts have also recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of Ćterna Zentaris in a research report on Wednesday, May 9th. ValuEngine upgraded shares of Ćterna Zentaris from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Finally, Maxim Group set a $4.00 target price on shares of Ćterna Zentaris and gave the stock a “buy” rating in a research report on Wednesday, March 28th.

Shares of Ćterna Zentaris opened at $2.37 on Wednesday, according to MarketBeat. The stock has a market cap of $40.12 million, a price-to-earnings ratio of -1.76 and a beta of 0.90. Ćterna Zentaris has a 12-month low of $0.89 and a 12-month high of $3.29.

Ćterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its earnings results on Wednesday, March 28th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.13. The company had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.14 million. Ćterna Zentaris had a net margin of 6.95% and a negative return on equity of 106.80%. equities analysts expect that Ćterna Zentaris will post -0.05 EPS for the current year.

Ćterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Get a free copy of the Zacks research report on Ćterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ćterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ćterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply